News | Heart Valve Technology | February 18, 2019

FDA Approves IDE Study for Foldax Biopolymer Heart Valve Platform

Tria surgical aortic heart valve combines proprietary biopolymer material and valve design for lifetime hemodynamic performance and quality of life similar to natural human valves

FDA Approves IDE Study for Foldax Biopolymer Heart Valve Platform

February 18, 2019 — Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption (IDE) approval for an Early Feasibility Study of the Tria surgical aortic heart valve to treat aortic valve disease.

Using LifePolymer, a proprietary advanced biopolymer material,  and a proprietary valve design, the Tria heart valve is designed to be a lifetime valve with hemodynamic performance and quality of life similar to natural human valves but without using animal tissue or the side effects of long-term anticoagulants. Intended for use in transcatheter or surgical heart valve applications, the Tria heart valves are robotically manufactured to provide the highest level of quality and precision.

“We look forward to introducing the Tria heart valve to patients in the United States”, said Amit Patel, M.D., of the University of Utah, who will be serving as primary investigator in upcoming clinical trials. “With the Tria heart valve we have the opportunity to overcome the challenges with today’s heart valves. The Tria valve is truly a revolutionary option for the more than 1 million Americans who have moderate or severe heart diseases.”1

The complete Tria heart valve platform will include valves developed for use in aortic, mitral and tricuspid valve disease. The company plans to continue its development efforts and clinical trials, in pursuit of outside-the-U.S. (OUS) and U.S. regulatory approvals.

For more information: www.foldax.com

Foldax Gets $20 Million to Finance Innovative Heart Valve Technology

 

References

1. Heart Valve Society of America (2018, April 11). About the Heart Valve Society of America. Retrieved from http://www.heartvalvesocietyofamerica.org/more.html.

Related Content

News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
Subscribe Now